FDA, NMIS checks on meat processing plants for African Swine Fever

Marje Pelayo   •   November 8, 2019   •   344

MANILA, Philippines – The Food and Drug Administration (FDA) and the National Meat Inspection Service (NMIS) have been doing rounds in meat processing plants across the country.

According to Health Undersecretary and FDA Officer-In-Charge Eric Domingo, there is a total of 178 meat processing plants in the Philippines.

Tests have been conducted in 68 of these facilities and the results were negative of African Swine Fever (ASF).

“Tinitingnan natin ang kanilang mga planta tapos ang kanilang mga documents kung meron silang mga inspection at saka kung pasado sila sa lahat ng standards (We check their plants as well as their documents to determine if they do regular inspections and if they pass all the standards),” Domingo said.

The FDA is coordinating with the Department of the Interior and Local Government (DILG) for assistance in monitoring supplies in local public markets in relation to the ASF.

Domingo admitted that it is difficult to identify if a product is infected with ASF that’s why it is better to choose a brand that is FDA registered.

One popular delicacy during holidays is the cured or glazed ham.

According to a retailers’ group, they already have taken orders of ham but only a minimal volume as compared to last year.

One reason for this is consumers’ fear of the outbreak of ASF virus.

“What is a bit difficult to estimate right now is how much ham should we order and how much ham will people buy,” lamented Steve Cua, President of the Philippine Amalgamated Supermarkets Association.

Still, Usec. Domingo said ASF-infected meat may still be consumed.

“Hindi naman po ito nakakahawa ng sakit sa tao (ASF is not transferrable to humans),” Domingo clarified.

“Kaya po natin siya talaga pinipigilan kasi ayaw nating kumalat sa iba pa pong hayop sa Pilipinas (The reason for prevention is because we do not want it to infect other animals in the Philippines),” he concluded. MNP (with details from Rey Pelayo)

IATF approves Phl participation in COVID-19 vaccine clinical trials

Maris Federez   •   May 24, 2020

MANILA, Philippines — Upon the recommendation of the Department of Science and Technology (DOST), the Inter-Agency Task Force for the Management of Emerging Infectious Diseases (IATF-MEID) has approved the proposed participation of the Philippines in clinical trials that seek to formulate a potential vaccine against coronavirus disease 2019 (COVID-19).

Based on IATF Resolution No.39 dated May 22, 2020, the task force has also ordered the creation of a sub-technical working group which will be led by the DOST.

The group will be coordinating with the four collaborating organizations composed of the Department of Health (DOH), the Food and Drug Administration (FDA), the Research Institute for Tropical Medicine (RITM), and the World Health Organization (WHO) with regard to the said clinical trials.

The IATF has also issued a directive to the FDA to facilitate the processing of necessary permits for the conduct of the clinical trials in the country.

The collaborating organizations for the clinical trials are the Adimmune Corporation, Academia Sinica, Chinese Academy of Science- Guangzhou Institute of Biomedicine and Health, the Sinopharm – Wuhan Institute of Biological Products, and the Beijing Institute.

Once the clinical trials are undertaken, these will be included in the FDA’s requirements for the registration process for the vaccine and the application for certificate of registration to make the vaccine available in the market.

The Philippines has initially participated in the WHO’s clinical trials, which include the testing of off-label drugs that show potential of being effective against COVID-19.

Meanwhile, the IATF has also approved the plans of the DOST to construct research centers for the local vaccine research development.

These include the Virology S&T Institute at the New Clark City in Tarlac and the reactivation of the Pharmaceutical Development Unit of the DOST-Industrial Technology Development Institute. —(from the report of Rosalie Coz) /mbmf

DOH admits COVID-19 testing capacity still below 8,000 to 10,000 daily target

Marje Pelayo   •   April 29, 2020

MANILA, Philippines — The Department of Health (DOH) on Wednesday admitted that the country’s testing capacity for coronavirus disease (COVID-19) is still below the target.

The Department had planned to expand its mass testing to 8,000 – 10,000 tests daily starting Thursday (April 30).

But, according to Health Undersecretary Maria Rosario Vergeire, they may not be able to achieve the target as scheduled.

Mukhang hindi po aabot dito sa walong libo for April 30, though sinusubukan natin dahil ngayon po dumating na ang cartridges natin for GeneXpert [I don’t think we can achieve the 8,000 target for April 30 though we are trying, especially with the arrival of the cartridges for GeneXpert,]” the official said.

The DOH was able to conduct a total of 6,320 tests on Tuesday (April 28) in 19 licensed testing laboratories across the country. 

Vergeire noted the recent scaling down of operations at the Research Institute for Tropical Medicine (RITM) as one reason for the delay in testing of samples which left the processing of results pending for about a week.

The RITM has just resumed full operations on Sunday after more than 30 of its COVID-19 positive medical staff recovered from the disease.

With the use of GeneXpert test kits, the DOH expects the results to be out within 45 minutes which will definitely improve the country’s testing capacity and hopefully achieve its daily target.

“But ngayon po itong ating goal ay pilit na maabot, aabutin [We will try hard to achieve our goal in] the coming days as all the resources had been falling in coming from private side and coming from the government,” Vergeire said.

Meanwhile, the Food and Drug Administration (FDA) has added a polymerase chain reaction (PCR) test kit from Singapore and two brands of rapid antibody test kit from Germany and China among the list of approved test kits that may be used in hospitals across the country.

To date, the country has a total of 33 FDA-approved PCR-based test kits and 24 rapid antibody test kits. 

The DOH reminds the public, however, that these test kits may only be administered by licensed doctors and experts who are also authorized to interpret test results. –MNP (with details from Aiko Miguel)

FDA approves 16 COVID-19 rapid test kits

Aileen Cerrudo   •   April 20, 2020

The Food and Drug Administration (FDA) has approved 16 coronavirus disease (COVID-19) rapid antibody test kits for commercial use.

“These applications have completed necessary documentary requirements and have undergone review and evaluation by the FDA,” according to the FDA in a statement.

The rapid test kits detect the presence of antibodies in an individual’s blood or serum. This is to determine if the individual has previously contracted the coronavirus and developed antibodies for it.

FDA Director General Eric Domingo previously said they want people to have access to the testing kits but the testing should still be subjected to proper protocols.

“The rapid test kits will yield a faster result compared to PCR based kits, but it is important that a trained health professional will evaluate and interpret the results,” he said.

The FDA, moreover, reminds the public that each rapid test kits have different specifications and the tests should still be administered by trained health professionals.

“The agency reiterates that these kits are strictly for medical professional use only and not intended for personal use,” the statement reads.

REACH US

The Philippine Broadcast Hub

UNTV, 915 Barangay Philam,

EDSA, Quezon City M.M. 1104

(+632) 8396-8688 (Tel)

info@untv-newsandrescue.com (General inquiries)

ABOUT UNTV

UNTV is a major TV broadcast network with 24-hour programming. An Ultra High Frequency station with strong brand content that appeal to everyone, UNTV is one of the most trusted and successful Philippine networks that guarantees wholesome and quality viewing experience.